DONGKOO BIO & PHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,810 KRW | +20.34% |
|
+24.17% | +37.99% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 2,40,580 | 2,32,556 | 1,69,609 | 1,56,349 |
| Enterprise Value (EV) 1 | 2,34,738 | 2,24,750 | 1,68,795 | 1,77,255 |
| P/E ratio | 25.8 x | 24.9 x | 25.8 x | 13.2 x |
| Yield | - | 1.22% | 1.79% | 2.12% |
| Capitalization / Revenue | 1.73 x | 1.5 x | 0.87 x | 0.72 x |
| EV / Revenue | 1.69 x | 1.45 x | 0.87 x | 0.82 x |
| EV / EBITDA | 19.4 x | 17 x | 7.51 x | 8.59 x |
| EV / FCF | - | 2,24,15,189 x | -1,20,19,98,871 x | -1,15,44,401 x |
| FCF Yield | - | 0% | -0% | -0% |
| Price to Book | 2.5 x | 2.3 x | 1.66 x | 1.42 x |
| Nbr of stocks (in thousands) | 28,812 | 28,291 | 27,624 | 27,624 |
| Reference price 2 | 8,350 | 8,220 | 6,140 | 5,660 |
| Announcement Date | 21/03/22 | 21/03/22 | 20/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 1,39,216 | 1,55,149 | 1,94,988 | 2,15,686 |
| EBITDA 1 | 12,117 | 13,193 | 22,469 | 20,644 |
| EBIT 1 | 7,611 | 8,139 | 16,836 | 14,616 |
| Operating Margin | 5.47% | 5.25% | 8.63% | 6.78% |
| Earnings before Tax (EBT) 1 | 10,300 | 11,333 | 7,916 | 14,741 |
| Net income 1 | 9,140 | 9,327 | 6,614 | 11,812 |
| Net margin | 6.57% | 6.01% | 3.39% | 5.48% |
| EPS 2 | 323.1 | 330.0 | 238.3 | 427.6 |
| Free Cash Flow | - | 10,027 | -140.4 | -15,354 |
| FCF margin | - | 6.46% | -0.07% | -7.12% |
| FCF Conversion (EBITDA) | - | 76% | - | - |
| FCF Conversion (Net income) | - | 107.51% | - | - |
| Dividend per Share | - | 100.0 | 110.0 | 120.0 |
| Announcement Date | 21/03/22 | 21/03/22 | 20/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | 20,906 |
| Net Cash position 1 | 5,842 | 7,806 | 814 | - |
| Leverage (Debt/EBITDA) | - | - | - | 1.013 x |
| Free Cash Flow | - | 10,027 | -140 | -15,354 |
| ROE (net income / shareholders' equity) | - | 9.58% | 6.54% | 11.1% |
| ROA (Net income/ Total Assets) | - | 3.4% | 6.44% | 5.03% |
| Assets 1 | - | 2,74,223 | 1,02,718 | 2,34,786 |
| Book Value Per Share 2 | 3,346 | 3,571 | 3,696 | 3,999 |
| Cash Flow per Share 2 | 173.0 | 697.0 | 453.0 | 569.0 |
| Capex 1 | 5,268 | 4,266 | 4,978 | 13,845 |
| Capex / Sales | 3.78% | 2.75% | 2.55% | 6.42% |
| Announcement Date | 21/03/22 | 21/03/22 | 20/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +37.99% | 16Cr | |
| +32.09% | 69TCr | |
| +29.39% | 58TCr | |
| -1.34% | 37TCr | |
| +20.34% | 33TCr | |
| +7.39% | 29TCr | |
| +14.25% | 24TCr | |
| -3.03% | 21TCr | |
| +10.02% | 21TCr | |
| +8.49% | 17TCr |
- Stock Market
- Equities
- A006620 Stock
- Financials DongKoo Bio & Pharma Co., Ltd.
